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ABSTRACT 
Despite significant advances in surgical procedures and treatment, long-term 
prognosis for patients with oral cancer remains poor, with survival rates among the 
lowest of major cancers. Better methods are desperately needed to identify potential 
malignancies early when treatments are more effective.  
Objective: To develop robust classification models from cytology-on-a-chip 
measurements that mirror diagnostic performance of gold standard approach involving 
tissue biopsy. 
Materials and Methods: Measurements were recorded from 714 prospectively 
recruited patients with suspicious lesions across 6 diagnostic categories (each 
confirmed by tissue biopsy -histopathology) using a powerful new Ôcytology-on-a-chipÕ 
approach capable of executing high content analysis at a single cell level. Over 200 
cellular features related to biomarker expression, nuclear parameters and cellular 
morphology were recorded per cell. By cataloging an average of 2,000 cells per patient, 
these efforts resulted in nearly 13 million indexed objects.  
Results: Binary Òlow-riskÓ/ Òhigh-riskÓ models yielded AUC values of 0.88 and 
0.84 for training and validation models, respectively, with an accompanying difference in 
sensitivity + specificity of 6.2%. In terms of accuracy, this model accurately predicted 
the correct diagnosis approximately 70% of the time, compared to the 69% initial 
agreement rate of the pool of expert pathologists. Key parameters identified in these 
models included cell circularity, Ki67 and EGFR expression, nuclear-cytoplasmic ratio, 
nuclear area, and cell area.  
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Conclusions: This chip-based approach yields objective data that can be 
leveraged for diagnosis and management of patients with PMOL as well as uncovering 
new molecular-level insights behind cytological differences across the OED spectrum. 
 
Highlights 
¥ Cytology-on-chip approach permits rapid molecular and morphometric analysis 
¥ Stable, robust predictive models created from single-cell data 
¥ Prognostic cytology features identified including cell circularity, Ki67 expression 
¥ Unique combination of parameters required for different diagnostic splits 
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INTRODUCTION 
It is estimated that 1-2% of adults in the United States present with a worrisome 
white or red patch or other potentially malignant oral lesion (PMOL) during a routine oral 
examination [1]. However, the vast majority of these lesions are benign, and only 1-2% 
will undergo progression into oral squamous cell carcinoma (OSCC) [2,3]. Oral 
healthcare providers are often the first line of defense in the early detection of oral 
cancer and are faced with the challenge of recognizing PMOL and deciding which 
patients to refer for tissue biopsy. This often difficult decision is becoming increasingly 
burdensome, confounded by the desire to reduce unwarranted biopsies and patient 
discomfort with the changing landscape of litigation directed at dentists for failing to 
refer patients [4]. To make matters worse, in PMOL, the histopatholgical diagnosis of 
oral epithelial dysplasia (OED) is not necessarily predictive of future malignant 
transformation, creating a demand for more sophisticated early risk assessment tools 
[5].  
Though decades of studies aimed at developing non-invasive, adjunctive aids for 
monitoring oral lesions have not garnered widespread adoption [6], a new era of rapid, 
quantitative, and automated tools are beginning to pave the way towards data-driven 
clinical decision making. Recent advances in a diverse consortium of fields from 
automated sample processing to statistical machine learning, microfluidic-based single-
cell analysis [7Ð9], and high content analysis/screening [10Ð14] have fueled a renewed 
interest in quantitative oral cytology. While offering strong potential for enhanced clinical 
insight relative to early disease detection, the Ò-omicsÓ data derived from these new 
capabilities has a tendency to yield putative clinical models that do not perform as well 
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in later validation studies. A recent review of 28 studies involving molecular classifiers 
by Castaldi et al. (2010) [15] found that the majority selected cross-validation practices 
that overestimated model performance [by ~17% (median) in terms of specificity].  
To address these challenges, our team of bioengineers, oral medicine clinicians, 
oral and maxillofacial pathologists, and cancer biologists, designed and executed a 
prospective, international clinical study with the ultimate goal of equipping dental 
practitioners with simple, automated, quantitative risk assessment tools to assist in 
making difficult biopsy referral decisions. Here we describe this single-cell cytology-on-
a-chip approach in the context of developing a multi-parameter image-based clinical 
decision tool.  
The general method for collection and processing of cells within a microfluidic 
structure was demonstrated previously in the context of a small pilot study involving 52 
patients using the single biomarker, EGFR, in order to differentiate between normal 
mucosa and OSCC [16]. The pilot yielded preliminary logistic regression models with 
sensitivity and specificity of 97% and 93% respectively, alongside area under the 
receiver operating characteristic (ROC) curve (AUC) equal to 0.94. These promising 
results paved the way for this more comprehensive follow-up with a Phase 2/3 clinical 
characterization-association study.  
Many previous quantitative cytology studies have confirmed that measureable 
differences exist between the extreme phenotypes of normal mucosa/benign lesions 
and malignant lesions [17Ð19] such as the increased proportion of small, highly circular 
cells that resemble more primitive stem cells. Though these differences can be 
surmised by visual examination by experts and non-experts alike, they miss the more 
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subtle spectrum of changes seen in PMOL representing the different grades of OED 
described by histopathologists [20]. An attempt to leverage the subtle measureable 
differences among OED cytology samples in order to develop objective classification 
models for PMOL has not existed until now.  
 
MATERIALS AND METHODS 
Study Population 
This study was approved by the Institutional Review Boards of all participating 
institutions. Informed consent was obtained for all participants in the trial after the 
possible consequences of the procedures were explained. The study design and clinical 
protocol for this study have been reported previously in detail [21]. Briefly, lesion 
samples from a total of 714 patients were measured, of which 85 were previously 
diagnosed malignant cases. The slight enrichment of the malignant cases allowed for a 
more substantial model development process with more equivalent class sizes. All other 
patients were prospectively recruited based on their exhibiting PMOL for which scalpel 
biopsy was a necessary part of the standard clinical practice. Histopathological 
assessment of biopsy specimens was used to place lesions in one of six categories of 
oral epithelial dysplasia (OED). These comprised 348 benign, 49 mild dysplasia, 18 
moderate dysplasia, 12 severe dysplasia, 2 carcinoma in situ (CIS), and 135 malignant 
lesions in addition to 150 healthy controls. To obtain greater confidence in the gold-
standard pathological diagnoses, which have been notoriously unreliable [22,23], a 3-
stage adjudication and consensus review process was performed which achieved 100% 
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consensus agreement from an initial 69.9% agreement rate between any two 
pathologists [21].  
A summary of the major variables analyzed is provided in the Supplementary 
Methods and Supplementary Tables 1-3. The molecular biomarkers EGFR, αvβ6, 
CD147, β-catenin, MCM2, and Ki67 were selected based on their capacity, through 
prior immunohistochemistry studies, to distinguish stages of disease progression 
towards OSCC for patients with PMOL.  
Cytology-on-a-chip Sample Processing 
Specific details for cytology-on-a-chip sample processing can be found in the 
Supplementary Methods and are adapted from the indirect-immunoassay protocol 
described in Weigum, et. al. (2010) [16]. In summary, sample processing comprised the 
following steps: 1) the microfluidic device was primed with PBS at a flow rate of 
735µL/min for 2 minutes, 2) a cell suspension in 20% glycerol/0.1% PBSA was 
delivered at 1.5mL/min for 2 minutes whereby single cells were captured on an 
embedded nanoporous membrane, 3) cells were washed with PBS at 1mL/min for 
2.5min, 4) a primary antibody solution was delivered through a 0.2µm PVDF syringe 
filter at 250µL/min for 2.5min, 5) a wash step similar to step 3 was performed, 6) a 
secondary antibody solution was delivered under the same conditions as step 4, 7) a 
final wash step was performed, and 8) fluorescence images were automatically 
captured.  
Data Processing   
Unlike most biomarker classification models that are developed with a single 
measure for each biomarker per patient, this study cataloged an average of 2,000 cells 
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per patient, resulting in nearly 13 million indexed objects, each with over 200 unique 
measurements to digitize biomarker expression profiles, and cytoplasm and nuclear 
morphology. To reduce the magnitude of this database to a computationally appropriate 
size, statistical measures were used to represent the magnitude and distribution of 
cellular features for individual patients. These included: mean, median, variance, 
standard deviation, coefficient of variation (CV), skewness, kurtosis, 10th/25th/75th/90th-
percentiles, and z-scores of 0.5, 2.0, and 3.0 referring to the proportion of cells with 
biomarker values greater than 0.5/2.0/3.0 standard deviations from the mean. A more 
detailed description of the complete set of variables used in this study can be found in 
Supplementary Tables 1, 2, and 3. In order to develop predictive models, the data was 
split into optimization, training, and testing sets with 250, 311, and 153 patients, 
respectively. 
RESULTS 
We have previously reported on the ability to isolate and interrogate single-cells 
within microfluidic structures for immunophenotyping [24Ð26], bacterial spore detection 
[27], and oral exfoliative cytology [28,16,29]. In addition to cell capture, the microfluidic 
device also serves as a delivery system for efficient transport of fluorescently-labeled 
antibodies and wash buffer. This cytology-on-a-chip methodology permits concurrent 
analysis of molecular biomarker expression and cellular/nuclear morphology using over 
200 fluorescence intensity and shape parameters for each identified cell extracted from 
multi-spectral fluorescence images (Fig. 1, Panel II and Supplementary Figure 1). The 
time to complete this chip-based image analysis is approximately 20 minutes following 
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sample preparation vs. about 1-3 days to complete a typical gold standard pathology 
exam.  
Model Development 
The completion of this clinical trial resulted in the formation of several different 
classification models used to correlate the biomarker signatures of individual patients to 
a pre-defined disease category. These categories were derived by dichotomizing the 
clinical spectrum of diagnoses at several cut-points (Fig. 2a) according to the 2005 
WHO 5-point histopathological grading system of OED [20] and the binary Òlow/highÓ-
risk grading system of OED proposed by Kujan et al [30]. 
Statistical machine learning techniques that minimize effect size inflation and 
selection bias were used to develop classification models, namely Random Forests 
using Òout of bagÓ validation and the L1-regularized logistic regression (LASSO) 
methodology. In addition, different subsets of parameters were evaluated consisting of 
biomarkers (molecular + morphometric), clinical lesion characteristics, and demographic 
risk factors (Supplementary Tables 1, 2). The goal of this approach was to obtain a 
sparse model to prevent data over-fitting and yield generalizable models with high 
stability. The classification models were fit to 2/3 of the data (training dataset) while 
blinded to the remaining 1/3 of the data (test dataset). Importantly, assays were 
completed in a blind fashion for all samples in the validation phase.  
In addition to creating classification models, random forests can be used to 
automatically probe variable importance in high dimensional datasets. Variable 
importance, quantified by the Gini-index decrease, can be interpreted as the relative 
ability of a specific parameter to discriminate between ÒcaseÓ and Ònon-caseÓ for the 
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diagnostic split in question, and is therefore an estimate of the informative value of a 
parameter. These results are summarized as a heatmap (Fig. 2b, c and Supplementary 
Figure 2).  
The key information here obtained reveals that molecular biomarkers are better 
suited for distinguishing benign lesions from earlier stage dysplastic + malignant lesions 
than for the higher diagnostic splits (cumulative normalized Gini-index ranges: 0.204 Ð 
0.810 (2|3), 0.137 Ð 0.554 (3|4), 0.139 Ð 0.540 (H|L), 0.111 Ð 0.432 (4|5)). Conversely, 
the morphometric parameters cell area, cell circularity, and NC ratio along with the 
proliferation biomarker Ki67 demonstrate high importance across all 4 dichotomous 
splits.  
To confirm the stability of the cytology dataset as it relates to model 
development, Gini-indices across 5 percentile summary measures (Fig. 2c) are 
compared to box plots of key variables (Fig. 2d). Variable importance is consistent with 
the observed biomarker trends for patients in different diagnostic categories. This key 
finding supports the development of stable models that translate the underlying 
biological phenomena into measures of variable importance.  
LASSO Automated Variable Selection 
The use of LASSO methodology helps prevent over-fitting a model by iteratively 
shrinking parameter effect sizes. The popularity of this method stems from its ability to 
automatically select the most influential variables and eliminate redundant model 
parameters that can be a major factor in high-dimensional data sets. A variable 
association visualization for the LASSO methodology is presented as a chord diagram 
(Fig. 3) where the chord width corresponds to the relative contribution of each 
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parameter to model performance across the 4 diagnostic splits, in terms of its 
standardized odds-ratio. 
Key parameters identified by the LASSO methodology include proliferation 
biomarker Ki67, cell area, cell circularity, nuclear area, and NC-ratio. Consistent with the 
random forest variable importance analysis, the odds-ratios from molecular biomarkers 
are found to play a more significant role in differentiating benign lesions from dysplastic 
+ malignant lesions than in models at other diagnostic splits (combined odds-ratios of 
9.558 (2|3), 3.337 (3|4), 4.087 (H|L), 3.253 (4|5)). Of the molecular biomarkers, Ki67 
provides the most discriminatory information with odds-ratios of 1.162 (median, log-
scale), 1.354 (10th percentile, log-scale), 1.184 (10th percentile, log-scale), and 1.307 
(10th percentile, log-scale) ((2|3), (3|4), (H|L), (4|5)). Several parameters demonstrate 
consistent model effects across all 4 diagnostic splits including cell area (average odds-
ratios of 0.835, 0.935, 0.969, 0.904), nuclear area (1.111, 1.023, 1.116, 1.028), and 
lesion size (1.139, 1.072, 1.124, 1.183), ((2|3), (3|4), (H|L), (4|5)). Furthermore, LASSO 
results indicated that each of the four diagnostic targets requires a unique combination 
of variables to achieve its highest performance. 
Cellular Phenotype Identified by Morphometric Parameters 
These key indicators for detecting dysplastic or malignant changes can also be 
leveraged along with the cytology image database created in this study to identify 
unique cellular phenotypes. In addition to routinely identified cell phenotypes such as 
binucleated cells and cells with micronuclei, 4 additional ÒcategoriesÓ are created to 
describe unique cell sub-populations. These categories are defined based on significant 
differences across the key parameters corresponding to smoothness of cytoplasmic 
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borders, cell circularity, cell area, nuclear area, NC-ratio, DAPI intensity, and Phalloidin 
intensity. The distribution of these custom phenotype labels for 300 randomized cells 
across 4 different patient diagnostic groups is compared (Fig. 4). Significantly higher 
proportions of cells that fit definitions for type B, C, D, and F in patients with OSCC are 
identified, referring to cells with higher than average circularity, higher NC-ratio, smaller 
overall cytoplasm area, enlarged nuclei, and those described as polynucleated. 
Morphometry-based phenotype identification also enables white blood cell (WBC) 
enumeration in cytology samples, an indicator with potential diagnostic utility that will be 
discussed in future publications. The ability to translate quantitative cytology metrics into 
visualizable cellular features has the potential to assist cytopathologists in discovering 
novel feature sets based on objective information. 
Model Performance 
 A single primary diagnostic model and numerous secondary models are 
selected by the study team through a rigorous process involving participation of three 
independent statisticians. This blinding process allows for this trial to complete both 
model development and model validation. The latter is accomplished in a fully blinded 
manner with the oversight of a contract research organization (Rho Inc., Chapel Hill, 
NC) using external data that is not employed for model development. A summary of the 
performance values obtained for the LASSO and random forest classification models is 
provided (Table 1).  
The study team selected the LASSO logistic regression model trained with the 
molecular biomarker and lesion characteristic datasets for differentiating ÒLow-riskÓ and 
ÒHigh-riskÓ lesions as the primary classification model in this study based on its superior 
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performance of the LASSO model in the development stage (based on averaged high 
sensitivity, specificity, and AUC). These efforts yield AUC values of 0.88 and 0.84 for 
the training and validation models, respectively.  
Across the training and validation datasets, the LASSO models that includes 
lesion characteristics outperforms those trained on biomarkers alone by boosting 
specificity an average of 6.56% (SD = 3.77%) (Sens: avg = -0.05%, SD = 4.31%; AUC: 
avg = 2.69%, SD = 1.28%). Interestingly, the addition of lesion characteristics did not 
appear to affect random forest models significantly (Sens: avg = -1.78%, SD = 2.19%; 
Spec: 3.34%, SD = 4.22%).  
On average, validation performance for random forests displays a 2.58% drop in 
sensitivity (SD= 3.50%) and an increase of 3.01% for specificity (SD=2.31%), compared 
to a 5.88% sensitivity drop for LASSO (SD = 5.07%) and a corresponding increase of 
3.79% in specificity (SD = 2.96%). Additionally, LASSO model AUCs decreases an 
average of 4.0% (SD = 2.41%) across the different diagnostic splits between the 
validation and training datasets. 
Parameters with significant information in discriminating between ÒLow-riskÓ and 
ÒHigh-riskÓ lesions selected by the primary LASSO model includes cell circularity (90th 
percentile), nuclear Ki67 intensity (10th percentile and coefficient of variation (cv)), cell-
surface EGFR intensity (standard deviation), NC-ratio (median), nuclear area 
(skewness and cv), cell area (25th percentile), and the lesion characteristics lichen 
planus and lesion size (long axis). Box plots illustrating the stable, monotonic trends of 
these variables across different diagnostic categories can be found in Supplementary 
Figure 3. 
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DISCUSSION  
In developing a chip-based approach to obtain a quantitative risk assessment for 
monitoring PMOL, this study sought to address three main questions: 1) Can a high 
content analysis (HCA) workflow be applied to primary patient cells? 2) How does 
model performance and composition change as a function of the diagnostic split 
position? 3) Can quantitative cytology tests produce diagnostic accuracy that rivals the 
gold standard pathology tests? Each of these key knowledge gaps is discussed below. 
Can HCA be applied to primary patient cells?  
Though HCA has been predominantly driven by screening applications involving 
cell lines grown in multi-well plates and advances in high-throughput laboratory 
automation, this study exemplifies how HCA can be applied to primary, patient-derived 
samples for personalized cellular scoring. This cytology-on-a-chip approach is unique in 
its ability to analyze hundreds of morphometric and biomarker expression parameters 
automatically across an entire cytology sample agnostic to clinical judgment or clinical 
history. In some instances, parameters that contributed to model performance and 
stability, such as NC-ratio, nuclear area, and Ki67 expression, confirmed previous 
reports of their roles in cyto- and histo-pathological grading [16],[17],[18],[31],[32].  
This study also identifies biomarkers that present new insights into how the 
quantification of cell and nuclear morphometry can provide rich data streams that track 
with the different grades of OED. In the primary LASSO model, two nuclear area 
measures (skewness and cv) are identified as important variables in discriminating 
between Òlow-riskÓ and Òhigh-riskÓ lesions. As summary measures of the distribution of 
nuclear area, both provide insight into the level of ansionucleosis (variation in size and 
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shape of nuclei [33]) for each patient sample, which is a prominent feature of dysplasia 
and malignancy [34],[33], but not often quantified. 
Cell circularity, a measure of the ÒroundnessÓ of the cytoplasmic membrane, is 
frequently identified in several models to be a highly performing parameter. An increase 
in cell circularity may be attributed to the decrease in the amount of cytoplasm and 
reduction in the degree of cellular cohesion which have both been reported to occur with 
increased dysplasia  grade [32]. The dominant summary statistic for cell circularity in 
these models is its 90th percentile measure, unlike the range of summary measures for 
cell area and NC-ratio, indicating cell circularity is skewed towards a fraction of cells 
with circularity measures in the upper 10% of the entire cell sample (Fig. 4 - cell types 
ÒBÓ and ÒCÓ).  
How does model performance change with diagnostic classification?  
One consistent finding from this study is that, at the higher end of the clinical 
spectrum (moderate-severe dysplasia cut-off), LASSO models (validation 
sens/spec/AUC = 85.7%/80.0%/0.883) and random forest models (validation sens/spec 
= 78.8%/68.3%) outperform models distinguishing low-grade lesions in terms of 
sensitivity, specificity, and AUC (Table 1). Longitudinal studies would be necessary to 
validate the malignant potential of these identified lesions. Histopathological grading has 
been shown to behave similarly, where higher accuracy and inter-observer agreement 
have been reported for high grade dysplastic or malignant lesions than for low grade 
dysplastic lesions, where considerable overlap from inflammatory and reactive changes 
can confound grading systems [35]. However, longitudinal studies are necessary to 
validate the malignant potential of these identified lesions. 
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Can quantitative cytology rival gold standard diagnostic accuracy?  
Though some drop in performance is expected between training and validation, 
similar values for these measures can indicate low risk of model over-fitting and greater 
generalizability. When comparing model performance between training and validation 
datasets across all 4 diagnostic splits in this study, random forest models displayed the 
greatest stability, with a mean difference of 2.58% for sensitivity (SD: 3.50%) and 3.01% 
for specificity (SD: 2.31%). The LASSO models demonstrated fair stability with a mean 
difference of 5.88% for sensitivity (SD: 5.07%) and 3.79% for specificity (SD: 2.96%). 
Indeed, robust classification models are developed that accurately mirrored the 
performance of histopathological assessment by expert pathologists. In terms of 
accuracy, the Òlow/high-riskÓ model accurately predicted correct diagnoses 
approximately 70% of the time, compared to the 69% initial agreement rate of the pool 
of expert pathologists. Furthermore, the level of agreement between model 
development and model validation far exceeds typical studies as reported by Castaldi et 
al. (2010) [15]. Furthermore, the design of the model development process presented 
here championed an additional level of rigor to ensure future generalizability and the 
absence of human bias which included oversight from a contract research organization, 
three layers of blinding to the true classification of patient lesions, two sets of 
independent biostatisticians, and utilization of statistical methods that performed 
automatic feature selection. 
In addition to the objective information that can be obtained with quantitative 
cytology, the Ôcytology-on-a-chipÕ technique presented here is amenable to complete 
process automation due to its foundations in microfluidic reagent handling, image 
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acquisition, and computational algorithms.  Future portable analyzers, similar to those 
being developed in the McDevitt lab [37], will have the potential to bring sophisticated 
tools for monitoring PMOL in patients with suspicious lesions to regions with limited 
access to expert pathologist review.   
 
CONCLUSIONS 
We have demonstrated the utility of a new cytology-on-chip that is capable of 
high-content, single-cell analysis across cellular and nuclear morphometric and 
molecular biomarker expression measurements. This new clinical decision tool has 
been developed and validated in the context of a major clinical study and has resulted in 
a rich database that has been exploited to develop new routines that provide insights 
into cytology characteristics associated with PMOL. These efforts demonstrate robust 
clinical performance and stable parameters for LASSO models with sensitivity and 
specificity values of ~85% and 70% in the model development phase and similar values 
(within 7%) in the validation phase.  
Additionally, superior model performance is found to be associated with 
heterogeneous data sources. Models trained on data from biomarker expression, 
morphometric features, clinical impressions, and patient risk factors achieves superior 
performance compared to models trained on restricted data. This essential finding has 
implications for future diagnostic applications and adjunctive aid development by 
emphasizing the need to integrate several different sources of information into a 
successful risk assessment rather than relying on the expression of a single biomarker 
or feature. 
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Figure Captions 
Figure 1 - Diagram of cytology-on-a-chip processing and sample images. Panel I.) Representative 
histopathological (H&E staining) images (A-B) and immunofluorescence-cytology images (C-D) for 4 
different patients. (A, C) are derived from Benign (Fig. 1.II.A = lichen planus diagnosis) and (B, D) from 
OSCC diagnoses as confirmed from independent agreement between two reviewing pathologists. Scale 
bars for A, B, C, and D = 100 µm. Panel II.) Diagram of Òcytology-on-chipÓ sample processing in which a 
brush cytology sample is collected (A), processed in a suspension, and delivered through the microfluidic 
platform (B) to a cell-capture, nano-porous membrane (C). Multi-spectral fluorescence images are 
recorded (D) and analyzed with automated software to identify single cells (E) and extract these regions 
for measurement (F). 
Figure 2 - Variable importance from Random Forest models. A) Visual representation of diagnostic 
spectrum and the 4 diagnostic splits used in this trial to dichotomize diagnoses into either ÒCaseÓ or ÒNon-
caseÓ. B) Univariate heat map of Gini values resulting from Random Forest modeling to demonstrate 
variable importance across all 4 diagnostic splits (y axis). Gini values from each model were scaled 
between 0 and 1 to generalize relative variable importance across all models. A value of 1 implies the 
variable is better able to discriminate between ÒcaseÓ and Ònon-caseÓ than a variable with a value closer 
to 0. Groups of parameters are labeled by their corresponding marker; single boxes represent specific 
summary measures (see Supplementary Figure 2 for more detailed labeling). Heatmaps should not be 
interpreted as ÒexpressionÓ, but rather as the information content associated with each parameter in its 
ability to differentiate between ÒcaseÓ and Ònon-caseÓ. C) Parameter subset from (B) to focus on summary 
percentile measurements (p10, p25, p50, p75, p90 = 10
th
, 25
th
, 50
th
, 75
th
, 90
th
 percentile values).  D) Box-
and-whisker plots showing the distribution of median values for Circularity (unit-less value between 0 and 
1), Ki67 (units = arbitrary fluorescence units (afu), nuclear-to-cytoplasmic (NC) ratio (unit-less ratio), and 
Cell Area (units = px
2
), respectively. The box bottom and top represent the 25
th
 and 75
th
 percentiles, 
respectively. Median values are connected between boxes, and whiskers down/up to 1.5 interquartile 
range. (Ben = ÒbenignÓ, Mild = Òmild dysplasiaÓ, Mod+ = Òmoderate/severe/CIS dysplasiaÓ, Mal = 
ÒmalignantÓ). 
Figure 3 - Chord Diagram of LASSO model parameter odds-ratios. Chord width refers to the relative 
contribution of a particular variable, based on standardized odds-ratios, calculated by exponentiating 
individual parameter coefficients from the logistic regression models. Odds-ratios of single parameters 
represent the odds that a model will predict the ÒCaseÓ diagnosis for an increase of one standard 
deviation for the standardized (unit-less) parameter while holding all other parameters constant. Model 
splits are identified on the right side and their corresponding variables on the left side. Parameters are 
further color-coordinated by categorical grouping: Lesion characteristics (L. Size = Lesion Size, L. Color = 
Lesion Color, LP = presence of the clinical features of lichen planus), Nuclear parameters (NC = NC-ratio, 
Nuc Area = nuclear area), Biomarkers (αvβ6, CD147, EGFR, Ki67, MCM2), and Cytomorphometric 
parameters (circularity, cell area). Summary statistic measures include A: coefficient of variation, B: 
variance, C: median, D: 10
th
 percentile, E: 25
th
 percentile, F: 75
th
 percentile, G: 90
th
 percentile, H: 
skewness, I: standard deviation, J: >0.5 Z-Score, K: >2.0 Z-Score, L: short-axis, M: long-axis, *: Log-
scale, 
2
:squared  
Figure 4 - Cellular Phenotype Identified by Morphometric Parameters. Panel I) Scatterplot and 
density histograms for two morphometric parameters (Maximum Feret diameter and mean Phalloidin 
intensity) used to distinguish sub-populations of cells. Panel II) Bar plot of cell counts for each of the 
phenotypes identified by Panel III for 300 randomly selected cells from patients with final adjudicated 
diagnoses in categories ÒNormalÓ, ÒBenignÓ, ÒDysplasticÓ (including mild, moderate, severe dysplasia and 
CIS), and ÒOSCCÓ. These plots are visualized as a continuous line where peaks refer to the number of 
cells identified in each case in order to illustrate a Òphenotype fingerprintÓ of the disease categories. Panel 
III) Representative images of unique cellular phenotypes identified by significant differences in key 
morphometric parameters. Each thumbnail is cropped to the same dimensions of 120 µm x120 µm. 
Phenotypic categories included A) Cells with smooth cytoplasmic border and high circularity, but low NC-
ratio, B) Cells with high circularity, high NC-ratio, and medium cytoplasm area, C) Cells with high 
circularity, high N-C ratio, and small cytoplasm area, D) large cells with enlarged nuclei, E) Binucleated 
cells, F) Polynucleated cells, G) Cells with micronuclei, and H) Normal appearing squamous cells.  
Table 1. Final model performance values for LASSO and random forest models. (ÒLC = 
parameter set with of lesion characteristics; Sens = sensitivity, Spec = specificity, AUC 
= area under ROC curve). 
 
      Training  Validation 
  Dichotomous split  Parameters  Sens %  Spec %  AUC  Sens%  Spec%  AUC 
La
ss
o
  
 
Low || High  Biomarkers Only  90.8  58.7  0.871  85.0  59.2  0.802 
  Biomarkers + LC  90.7  64.5  0.884  78.6  70.4  0.836 
               
Benign || Mild  Biomarkers Only  90.1  45.0  0.814  92.7  53.1  0.800 
  Biomarkers + LC  89.9  52.0  0.844  89.1  55.1  0.846 
               
Mild || Moderate  Biomarkers Only  89.7  60.1  0.869  82.9  60.5  0.809 
  Biomarkers + LC  89.6  67.2  0.880  82.9  72.3  0.839 
               
Moderate || Severe  Biomarkers Only  89.4  72.6  0.903  77.1  73.6  0.846 
  Biomarkers + LC  90.8  73.8  0.917  85.7  80.0  0.883 
                 
R
a
n
d
o
m
 F
o
re
st
 
Low || High  Biomarkers Only  89.5  51.1  ‐  86.8  53.0  ‐ 
  Biomarkers + LC  89.3  51.3  ‐  86.8  51.3  ‐ 
               
Benign || Mild  Biomarkers Only  91.0  42.0  ‐  90.9  50.0  ‐ 
  Biomarkers + LC  89.0  48.0  ‐  90.9  52.0  ‐ 
               
Mild || Moderate  Biomarkers Only  89.7  49.4  ‐  87.2  51.8  ‐ 
  Biomarkers + LC  87.0  50.4  ‐  87.2  52.6  ‐ 
               
Moderate || Severe  Biomarkers Only  90.9  56.3  ‐  84.9  59.2  ‐ 
  Biomarkers + LC  87.7  65.6  ‐  78.8  68.3  ‐ 
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Supplementary Methods 
 
Rationale on Biomarker Selection  
In addition to EGFR (epidermal growth factor receptor) which was studied in our previous trial
1
, 
the biomarker selection was expanded to 5 additional molecular biomarkers (αvβ6, CD147, β-catenin,  
MCM2 (Minichromosome Maintenance Complex Component 2), and Ki67). These markers fall 
predominantly into two groups: 1) cell surface markers: αvβ6 (an integrin receptor undetectable in normal 
oral epithelium, but highly expressed in dysplasia and OSCC
2,3
); CD147 (EMMPRIN) (a multifaceted 
molecule that facilitates tumor progression by several mechanisms
4
); β-catenin (a transcription factor in 
the Wnt pathway, which promotes transcription of genes involved in cellular proliferation and apoptosis 
inhibition
5
); EGFR (a transmembrane glycoprotein whose overexpression may contribute to tumor 
progression
5
); and 2) nuclear markers of proliferation/cell cycle regulation: MCM2 (an essential 
component for DNA replication associated with deregulated expression in dysplastic and malignant 
epithelial cells
6,7
); Ki67 (a marker of proliferation that is overexpressed at initial stages of oral 
carcinogenesis
5
). 
 
Cytology-on-a-Chip Protocol  
Immediately after brush cytology samples were collected, cells were harvested by vortexing the 
brush head in minimum essential medium (MEM) culture media, followed by a PBS wash, re-suspension 
in FBS containing 10% of the cryo-preservative dimethyl-sulfoxide (DMSO), frozen, and stored in a -80
o
C 
freezer at the clinical site until samples were shipped in batches to the McDevitt Laboratory at Rice 
University.  
Prototype laminate microfluidic devices were assembled in-house by manually aligning separate 
component layers. The base layer was laser machined from 3/8Ó acrylic (McMaster Carr, Elmhurst, IL, # 
8774K42) to accommodate fluidic ports and a sub-membrane cavity. A stainless steel frit was embedded 
in the acrylic base as a membrane support. Directly over the frit, a polycarbonate track-etched membrane 
with 0.4µm pores was anchored by the fluid delivery adhesive channel assembly. These microfluidic 
channels were cut from double-sided adhesive film (DSA), vinyl, and thermoplastic film using a precision 
plotter cutter with sub-25-µm resolution (Summa D75, Summa Inc., Seattle, WA). Dimensions for the 
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device were as follows: channel height = 125µm, channel width = 1.2mm, and exposed membrane area = 
20mm
2
. 
Prior to processing on the microfluidic device, patient samples were thawed rapidly in a 37
0
C 
water bath, washed with PBS, and fixed for one hour in 0.5% formaldehyde prepared fresh from a 16% 
stock solution (Polysciences, Warrington, PA, #18814-20). After fixation, cells were washed twice in PBS, 
re-suspended in 150µL 0.1%PBS with 0.1% BSA (PBSA), and stored at 4
0
C until ready to process. 
Before sample delivery, the cell suspension was diluted in a 20% glycerol/0.1% PBSA solution to improve 
cell distribution across the membrane and to reduce cell clumping.  
Using a custom built manifold connecting external fluidic tubing to the inlet and outlet ports of the 
microfluidic device, the assembly was positioned on a robotically controlled microscope stage (ProScan 
II, Prior Scientific, Cambridge, UK) and connected to a peristaltic pump (SciQ 400, Watson Marlow, 
Wilmington, MA) and manually controlled 6-position injector valve (Vici, Valco Instruments, Houston, TX). 
Antibody stock solutions were vortexed for 30 seconds and centrifuged at 14,000rpm for 5min before 
preparing working dilutions to avoid precipitates.  
All microfluidic cytology-on-a-chip assays contained Phalloidin and DAPI in the secondary 
antibody cocktail, but each was specific for a single molecular biomarker primary-secondary antibody 
pair. Working dilutions of antibodies were prepared in 0.1%PBSA with 0.1% Tween-20 (EMD Millipore, 
Billerica, MA, # 655206). Primary monoclonal antibodies were raised from either mouse (EGFR (Life 
Technologies, Carlsbad, CA, #MS-378-P, 10µg/mL) and β-catenin (BD Transduction Labs, San Jose, CA, 
#610154, 20µg/mL)), rabbit (avb6 (Abcam, Cambridge, MA, #Ab124968, 6µg/mL), Ki67 (Abcam 
#Ab15580, 29µg/mL), and MCM2 (Abcam #Ab108935, 10µg/mL)), or goat (CD-147 (EMMPRIN) (R&D 
Systems, Minneapolis, MN, #AF972, 20µg/mL). AlexaFluor-488 conjugated secondary antibodies were 
specific for F (abÕ)2 fragments of mouse IgG (Life Technologies #A11017, 20µg/mL for EFGR and β-
catenin), rabbit IgG (Life Technologies #A11070, 50µg/mL for avb6, 64µg/mL for Ki67, and 23.5µg/mL for 
MCM2), or goat IgG (Life Technologies #A11078, 40µg/mL for CD147). A working concentration of 
0.33µM was used for Phalloidin-AlexaFluor-647 (Life Technologies #A22287) and 5µM for DAPI (Life 
Technologies #D3571). 
4 
 
In summary, the lab-on-a-chip sample processing was comprised of the following steps: 1) the 
device was primed with PBS at a flow rate of 735µL/min for 2 minutes, 2) the cell suspension in 20% 
glycerol/0.1% PBSA was delivered at 1.5mL/min for 2 minutes, 3) cells were washed with PBS at 
1mL/min for 2.5min, 4) the primary antibody solution was delivered through a 0.2µm PVDF syringe filter at 
250µL/min for 2.5min, 5) a wash step similar to step 3 was performed, 6) the secondary antibody solution 
was delivered under the same conditions as step 4, 7) a final wash step was performed, and 8) 
automated image capture was performed.  
 
Sample Digitization 
Images were recorded with a motorized reflected fluorescence microscope (Olympus BX-RFAA) 
equipped with a CCD camera (Hamamatsu ORCA-03G) through a 10x objective (10x/0.30NA UPlanFl, 
Olympus). A total of 25 unique fields of view (FOVs) repeated for 3 different z-focal planes were 
automatically captured across a 20mm
2
 area using a robotic x-y-z microscope stage. Due to the complex 
three-dimensional morphology of oral squamous cells, multiple z-focal planes were captured and 
subsequently combined into a single, enhanced depth-of-field image to simplify the multi-spectral 
detection of the three fluorescent labels using the Òstack focuserÓ macro built into ImageJ 
(http://rsb.info.nih.gov/ij/plugins/stack-focuser.html).   
Combinations of custom macros and the open-source image analysis tools ImageJ [30] and Cell 
Profiler [11] were developed to automatically detect individual cells and define their nuclear and 
cytoplasmic boundaries as individual regions of interest (ROI). These ROIs were used to obtain intensity 
measurements associated with the three spectral channels and were used to define morphometric 
parameters. The DAPI and Phalloidin molecular labels served primarily to assist in the automated 
segmentation of individual nuclei and cytoplasm, respectively.  
 
 
Random Forests 
Random forests are an ensemble modeling approach composed of a collection of single decision 
trees and have been shown to be extremely resistant to outliers [31]. During model development, 1,000 
randomly generated classification trees were fit to bootstrapped samples, with replacement. Each node of 
5 
 
the generated decision trees was fit to a randomly generated subset of 15 parameters. Initial random 
forest analyses used equal weights for Ònon-caseÓ and ÒcaseÓ with cutoff points of 0.5 and 0.5, 
respectively. Additional weights of (0.6, 0.4), (0.65, 0.35), and (0.7, 0.3) were used to adjust the decision 
weighing between Ònon-caseÓ and ÒcaseÓ, respectively. The sample weighting and choice of cutoff were 
manipulated in order to achieve approximately 90% and 85% sensitivities in the training models. The 
random models require that there are no missing independent variables, therefore two patients were 
excluded. 
 
LASSO L1-Regularized-Logistic Regression 
The LASSO methodology is a shrinkage and subset selection method that iteratively shrinks 
parameter effect sizes in order to help prevent against over-fitting. Model parameters identified by the 
LASSO methodology are the remaining parameters for each model after all other model parameter 
effects shrink to zero. Prior to LASSO model fitting, all parameters were standardized as z-scores. Model 
decisions were weighted to (2,1) for Ònon-caseÓ and ÒcaseÓ respectively for the benign-mild dysplasia split 
and (3,1) for all others. 
 
 
!  
6 
 
Supplementary Figures 
 
Supplementary  Figure 1. ÒCytology-on-a-chipÓ device evolution.  
A) Rendering of original Òflow cellÓ device used for cytology-on-a-chip measurements throughout the trial. The prototype device 
interfaced to external pumping and fluid handling equipment via two stainless-steel inlet and outlet ports. B) Rendering of flow cell 
7 
 
assembly with interchangeable fluid manifold. While not used for measurement collection in this trial, this improved chip-to-world 
interface has made subsequent assays more successful by reducing the occurrence of failures via inlet leaks. C) Rendering of form-
factor ÒcartridgeÓ device for next-generation cytology-on-a-chip sample processing (shown with protective shell). D) Rendering of 
same cartridge without shell to expose underlying network of microfluidic channels. While the ability to isolate and interrogate single 
cells across a micro-porous membrane is the same as the original flow cell (A), all assay operations following sample preparation 
(such as pumping, reagent filtering, and waste storage) are now contained within an integrated device.  E) Exploded diagram of 
original flow cell (A), enlarged to show detail of various layers of the assembly. The fluid path from inlet, across the membrane, and 
through the outlet is highlighted in blue.  
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Supplementary Figure 2. Heatmap of random forest variable importance based on 
Gini index.  
(Repetition of Fig. 2b, but enlarged to show individual labels. Explanation of labels can be found in Supplementary Table 3).a = 
benign/mild-dysplasia, b = mild/moderate-dysplasia, c = low-risk/high-risk, d=moderate/severe-dysplasia. 
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!
Supplementary Figure 3. Box and whisker plots of selected variables identified in 
primary LASSO model.  
These variables include a) cell circularity, 90
th
 percentile (log-squared); b) Ki67, 10
th
 percentile; c) Ki67, coefficient of variation (cv) 
(log-scale); d) EGFR expression, standard deviation (log-scale), e) NC ratio, median (log-squared); f) nuclear area, skewness; g) 
nuclear area, cv; and h) cell area, 25
th
 percentile. Ben: benign, Mild: mild dysplasia, Mod+: moderate/severe/CIS dysplasia, Mal: 
malignant. The box bottom and top represent the 25
th
 and 75
th
 percentiles, respectively. Median values are connected between 
boxes, and whiskers down/up to 1.5 interquartile range.  
!  
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Supplementary  Table 1. Detailed description of the different morphometric and 
biomarker measurements collected in this trial. 
 
Parameter Whole Cell Nucleus 
Im
a
g
e
 I
n
te
n
s
it
y
 (
W
h
o
le
 c
e
ll
, 
N
u
c
le
u
s
; 
R
/G
/B
 c
h
a
n
n
e
ls
) 
Mean intensity value 
WCMean[red], [green] NuMean[green], [blue] 
Average value within the whole cell or nucleus selection. This is the sum of the 
intensity values of all the pixels in the selection divided by the number of pixels. [red] 
has QA/QC value and [blue] has limited descriptive value, whereas [green] is the 
most important for surface markers. For intracellular markers, the NuMean[green] is 
most descriptive. 
Standard deviation of 
intensity 
WCStdDev[red], [green] NuStdDev[green], [blue] 
Standard deviation of the intensity values used to generate the mean intensity value. 
[red] useful for Phalloidin, QA/QC and descriptive, [green] for surface markers. 
Modal Value of 
intensity 
WCMode[red], [green] NuMode[green], [blue] 
Most frequently occurring value within the selection. Corresponds to the highest peak 
in the histogram. Similar to Mean in terms of value. 
Minimum and 
Maximum Intensity 
value 
WCMin and WCMax[r/g/b] NuMin and NuMax[r/g/b] 
Minimum and maximum intensity values within the selection. Limited descriptive 
value, may be used for QA/QC. 
Integrated density 
WCIntDen[r/g/b] NuIntDen[green], [blue] 
Calculates and displays "IntDen" (the product of Area and Mean Gray Value) Ð 
Dependent values. 
Median intensity value 
WCMedian[red], [green] NuMedian[green], [blue] 
The median value of the pixels in the image or selection. This again is similar to 
Mean and Mode in terms of utility. 
M
o
rp
h
o
m
e
tr
ic
 P
a
ra
m
e
te
rs
 
Area 
WCArea[red] NuArea[blue] 
Area of whole cell or nucleus selection in square pixels determined in red from 
Phalloidin stain. 
Perimeter 
WCPerim[red] NuPerim[blue] 
Length of profiled selection: whole cell or nucleus. Has value in QA/QC for evaluating 
profile. 
Circularity 
WCCirc[red] NuCirc[blue] 
A value of 1.0 indicates a perfect circle. As the value approaches 0.0, it indicates an 
increasingly elongated shape. Values may not be valid for very small particles. 
Calculated as 4π*area/perimeter
2
 
Feret Diameter 
WCFeret[red] WCFeret[blue] 
The longest distance between any two points along the selection boundary, also 
known as maximum caliper. 
Nuclear to Cytoplasmic 
(NC)-ratio 
N_to_C_ratio 
Critical value, calculated as ratio of  NuArea / WCArea. 
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Supplementary Table 1 (Continued). Detailed description of the different 
morphometric and biomarker measurements collected in this trial. 
Parameter Whole Cell Nucleus 
B
a
c
k
g
ro
u
n
d
 S
ig
n
a
l 
Overall Background 
Background[red], [green], [blue] 
The mean intensity of the entire image Ð may inform about non-specific binding 
of antibodies on membrane, or presence of large artifacts 
Signal to Background 
StoBWCMed[r/g/b] StoBNucMed[r/g/b] 
Measure of the signal to background ratio, with the signal measured as 
WCMed[r/g/b] or NuMed[r/g/b], and calculated as (signal Ð 
background)/background. 
StoBWCAve[r/g/b] StoBNucAve[r/g/b] 
Measure of the signal to background ratio, with the signal measured as 
WCMean[r/g/b] or NuMean[r/g/b], and calculated as (signal Ð 
background)/background. 
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Supplementary Table 2. Lesion characteristics and Demographic risk factor 
parameters and definitions. 
Lesion Characteristics 
Lesion with Diffuse Borders 
Lesion size (diameter along the long axis) 
Lesion size (diameter along short axis, i.e.  perpendicular  to long axis) 
Lesion area 
Lesion color red, or red/white, excluding lichen planus 
Lichen planus: binary measure completed by clinician at time of brush cytology sample collection where 
ÒPositiveÓ indicated the presence of the clinical features of lichen planus, and ÒnegativeÓ indicated the 
absence of such features 
Demographic Risk Factors 
Short Reference Description 
Age Age in years 
Sex Sex (Male:1; Female:0) 
Alcohol: 12 drinks in life Alcohol: 12 drinks in life  
Alcohol: 12 drinks in past 
year 
Alcohol: 12 drinks in past year 
Alcohol days per year Average days of alcohol use per year 
Drinks per day  Average number of drinks on days drinking  
Alcohol drink years Alcohol drink years (average drinks per day times number of years drinking 
>=100 Cigarettes in 
lifetime 
At least 100 cigarettes in lifetime 
Current cigarette smoker Smoke Cigarettes now 
Years smoking 
cigarettes 
How many years smoked cigarettes 
Cigarettes per day Average cigarettes smoked per day 
Tobacco Pack Years Combined Cigarette, Cigar/Pipe Pack Years.  Five cigars were considered 
equal 1 cigarette pack; and, 10 pipes were considered equal 1 cigarette 
pack. However since only combined pipe and cigar use was recorded: 7.5 
cigars/pipes were set equal 1 cigarette pack (mean of cigar and pipe 
cigarette pack equivalents. 
20 Cigars/ Pipes in life At least 20 cigars or pipes in lifetime 
Current cigar/pipe use Smoke Pipes or Cigars Now 
Years of Cigar/Pipe use Years Smoke Pipes or Cigars 
Cigars/Pipes per day Average Smoke Pipes or Cigars per day 
Cigar/Pipe years Pipes or Cigars per day times years 
Chew tobacco use in life Ever use chewing tobacco or snuff 
Current chew tobacco 
use 
Use chewing tobacco or snuff currently 
Years chewing tobacco 
or snuff 
Years chewing tobacco or snuff 
Containers chewing  or 
snuff per week 
Containers chewing  or snuff per week 
Chew Tobacco/snuff 
Container years 
Container Years chewing/snuff per day (average containers per day time 
years  
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Supplementary Table 2 (Continued). Lesion characteristics and Demographic risk 
factor parameters and definitions. 
 
Demographic Risk Factors 
Both high risk tobacco 
and alcohol use 
Combined high risk alcohol and tobacco use (> 20 equivalent 
cigarette/cigar/pipe pack years  and/or,  if male: an average of 2 or more 
drinks per day, or if female: an average of 1 or more drinks per day). 
>20 tobacco pack years  More than 20 cigarette pack years (or cigar/pipe pack year equivalents). 
!  
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Supplementary Table 3. Abbreviations and Full names of biomarker labels from 
Supplementary Figure 2 
Summary Statistic Measures 
Abbreviation Full name 
cv Coefficient of variation 
inter Variance 
kurt Kurtosis 
mean Mean 
med Median 
p10 10
th
 percentile 
p25 25
th
 percentile 
p50 50
th
 percentile 
p75 75
th
 percentile 
p90 90
th
 percentile 
skew Skewness 
std Standard deviation 
Z_0_5 
>0.5 Z-Score (percent of cells with biomarker values greater than 0.5 standard 
deviations away from healthy cells) 
Z_2_0 
>2.0 Z-Score (percent of cells with biomarker values greater than 2.0 standard 
deviations away from healthy cells) 
Z_3_0 
>3.0 Z-Score (percent of cells with biomarker values greater than 3.0 standard 
deviations away from healthy cells) 
Biomarker Names 
Abbreviation Full name 
AVB6 αvβ6 
C147 CD-147 (EMMPRIN) 
EGFR EGFR (epithelial growth factor receptor) 
KI67 Ki-67 
LNB Number of lone nuclei 
MCM2 MCM2 
NRAT Nuclear-to-Cytoplasmic area ratio 
NUAR Nuclear Area 
SPEK ÒSpeckled cellÓ Ð unidentified intermediate cells smaller than WBCs 
WBC White blood cells (count) 
WBCF White blood cells (fraction of total cells) 
WCAR Whole cell area 
WCIR Whole cell circularity 
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